Abstract 63P
Background
Pancreatic cancer is highly malignant and has a low cure rate. Traditional treatments are limited, and the potential of immunotherapy remains unrealized due to immune cell heterogeneity in the tumour microenvironment. Tumour-associated macrophages (TAMs), especially tissue-resident macrophages (TRMs), play complex roles in tumours.
Methods
We used single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (bulk-seq) data from pancreatic cancer patients in the GEO and TCGA databases. We analyzed macrophage heterogeneity and their functions in the tumour microenvironment. Using cell communication analysis and immune marker grading, we calculated a TAM score and analyzed survival prognosis, identifying macrophage subpopulations and their roles in tumour progression and immune response.
Results
We characterized the tumour microenvironment using scRNA-seq data and identified the TRM subpopulation. Cell communication analysis revealed interactions, including the CXCL/MIF interaction, between TRMs and various cell populations. TAM score calculations showed that TAM clusters 4, 5, 9, and 10 were significantly associated with survival risk. Predictive analyses for 5-year and 10-year mortality found that TRM cluster 4 had the highest predictive efficacy. Clinical feature analysis of patients with high and low TRM_C4 risk scores revealed significant differences in survival rates, immune cell infiltration, and immune checkpoint expression. Pre- and posttreatment TAM_C4 scores differed significantly between responders and nonresponders, with nonresponders showing increased posttreatment scores and responders showing decreased scores.
Conclusions
This study provides new insights into the heterogeneity of macrophages in pancreatic cancer and their roles in regulating tumour behaviour. Targeting specific macrophage subpopulations may lead to new therapeutic strategies, improving the effectiveness of immunotherapy and the outcomes for patients with pancreatic cancer.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract